Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to an expanded range of patients.
The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile.
That means more women with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2018 Category: Biotechnology Authors: Greg Avery Source Type: news
Dr. Nita Ahuja appointed the Carmalt Professor of Surgery
Ahuja is a surgeon and research scientist internationally renowned for her expertise in the management of peritoneal cancer metastases. (Source: Yale Science and Health News)
Source: Yale Science and Health News - March 22, 2018 Category: Universities & Medical Training Source Type: news
Quiz: Genetic Risk Evaluation for Fallopian Tube Cancer?
Should a patient with fallopian tube cancer undergo genetic risk evaluation? What is essential in post-treatment monitoring of ovarian, fallopian tube, and primary peritoneal cancers? Take this multiquestion quiz to find out. (Source: CancerNetwork)
Source: CancerNetwork - March 20, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Gynecologic Cancers Quiz Source Type: news
Activity matters: How Fitbit can help us understand cancer surgery recovery
(Oxford University Press USA) A new study published in Annals of Behavioral Medicine finds that more activity during inpatient recovery predicted lower risk of 30- and 60-day readmission after surgery for metastatic peritoneal cancer. By monitoring patients using Fitbit, researchers found that higher Fitbit steps forecast better patient outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2017 Category: Cancer & Oncology Source Type: news
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients.
The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile.
The FDA says it will make a decision by April 6, 2018,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 6, 2017 Category: Biotechnology Authors: Greg Avery Source Type: news
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients.
The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile.
The FDA says it will make a decision by April 6, 2018,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 6, 2017 Category: Pharmaceuticals Authors: Greg Avery Source Type: news
Is Peritoneal Cancer Hereditary?
Title: Is Peritoneal Cancer Hereditary?Category: Doctor's& Expert's views on SymptomsCreated: 10/13/2017 12:00:00 AMLast Editorial Review: 10/13/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 13, 2017 Category: Cancer & Oncology Source Type: news
Ovarian Fallopian Tube Primary Peritoneal Cancer
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news
ovarian epithelial fallopian cancer
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news
HIPEC for Colorectal Cancer With Peritoneal Carcinomatosis
This video reviews the use of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery in colorectal cancer with peritoneal carcinomatosis. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2017 Category: Cancer & Oncology Authors: Hans Schlitt, MD Tags: Videos Gastrointestinal Cancers Source Type: news
Case: Coccidioidomycosis Mimicking Peritoneal Carcinomatosis Case: Coccidioidomycosis Mimicking Peritoneal Carcinomatosis
New onset ascites, lymphadenopathy, and peritoneal nodules suggested a metastatic carcinomatosis in this patient; but her residence in Arizona provided the key to the correct diagnosis.Applied Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 8, 2017 Category: Radiology Tags: Radiology Journal Article Source Type: news
New Approaches Needed for Peritoneal Metastases in CRC New Approaches Needed for Peritoneal Metastases in CRC
Dr David Kerr challenges the oncology community to come up with rational, meaningful clinical trials to clarify the biology of metastatic peritoneal disease in colorectal cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 13, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
FDA Approves Niraparib for Recurrent Ovarian Cancer
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news
FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 27, 2017 Category: American Health Source Type: news
